Biogen Idec’s BG-12 achieves essential milestones in clinical trials for MS and RA Biogen Idec today announced that it is oral compound BG-12 achieved essential milestones in clinical trials for multiple sclerosis and arthritis rheumatoid oral capsules . Lately, the last individual was signed up for the CONFIRM trial, the next of two Stage III trials made to measure the efficacy and protection of BG-12 as a monotherapy in sufferers with relapsing-remitting multiple sclerosis . Both DEFINE and CONFIRM Stage III trials are actually fully enrolled and can evaluate the aftereffect of BG-12 on scientific relapse, disability progression, several MRI steps of disease activity, and basic safety.
About Biogen Through cutting-edge medicine and research, Biogen discovers, evolves and delivers to patients world-wide innovative therapies for the treating neurodegenerative diseases, hematologic circumstances and autoimmune disorders. Founded in 1978, Biogen is among the world’s oldest independent biotechnology companies and individuals worldwide reap the benefits of its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, pr announcements and additional information regarding the company, please visit.. PRESS RELEASE CAMBRIDGE, Mass.today —-Effective, Biogen Idec is well known simply asBiogen.